GENERIC INJECTABLE FOR VET MARKET 
The CEO of a venture funded, start-up veterinary products  firm needed help to identify partners for:

• formulation development
• analytical chemistry
• process development 
• clinical supplies 
• packaging
• commercial manufacturing
  

We worked with the company to identify their key priorities. Based on their requirements, we identified the best in breed for each capability as well as integrated service providers in the US and Asia.

STRATEGIC PLANNING
Kineticos Life Sciences was retained by the CEO of a life sciences reagents supplier to help develop a new strategic plan. The CEO had recently hired new leaders in Sales, Marketing, R&D, Finance and Supply Chain and had invested heavily in building a regional sales organization. These changes were helping to drive the top line 18% and the CEO and Board to accelerate the growth rate. We worked with the management team to evaluate the entire business including current products and new markets.

As a result of this plan, the company identified adjacent markets to enter that could double the company’s revenues in the next 3 years.

M & A – STRATEGIC OPTIONS
Kineticos Life Sciences was hired by the CEO of a reagents and kits supplier for the life sciences market to help evaluate strategic options for one of its business units. Within a very short time, we met with the head of the business unit as well as marketing, finance and operations executives to understand priorities. Based on these priorities, we recommended the following:

• Reorganize the business unit into separate service and product segments.
• Move the products segment which was profitable with significant new opportunities, into to a related business unit.
• Consolidate manufacturing and distribution for the products segment with two other underutilized locations.
• Divest the services business which was losing money and did not fit the company’s long term strategy.
• Move the VP, R&D, a well respected industry veteran, to a third business unit which had recently lost its R&D head.
  

These actions reduced expenses by $1.1 million and advanced new growth opportunities worth in excess of $2.3 million.